Research
Eye cancer is a rare disease, meaning treatment efforts across the world vary and that access to care is not always readily available. The Eye Cancer Foundation supports research efforts that will advance treatment methods and overall the rate at which eyes and lives are saved. With research, eye cancer can be treated.
- Bioinformatic Grid (BIG): The mission of the eye cancer bioinformatics grid is to provide an infrastructure for sharing data, results and research. Dr. Finger says, “There is power in numbers!” Learn more here >
- Working Days: The Working Day unites specialists around the globe to develop multicenter, international collaboration in ocular oncology. The second Eye Cancer Working Day took place March, 24, 2017 in Sydney, Australia. The first Eye Cancer Working Day was held at the Curie Institute in Paris, France on June 15, 2015. Learn more here >
- The Essential Eye Cancer Podcast: The podcast's main purpose is to inform, educate and disseminate topical information about eye cancer and the research being done. Learn more here >
- The Eye Cancer Foundation's Official YouTube Videos: The Eye Cancer Foundation has many lectures and informational topics discussed by Dr. Paul T. Finger on our YouTube channel. Visit this page to see a list of videos. Learn more here >
- The Titus Fund: The Eye Cancer Foundation has partnered with Mr. Titus Lennon, a survivor of schwannoma, for a special project. Learn more here >
- Liberty Vision Y90: Dr. Paul Finger, CEO and chairman of The Eye Cancer Foundation has implemented the first clinical trial for Yttrium-90 (Y90) Disc Brachytherapy after FDA clearance! Learn more here >
- International Retinoblastoma Comprehensive Course (IRBCC): The International Retinoblastoma Comprehensive Course (IRBCC) was designed to serve as a foundational element for eye cancer specialists. It was prepared by more than 50 internationally renowned experts to provide detailed practical guidance and advice on the diagnosis and management of retinoblastoma (RB). Learn more here >
- Newly Obtained Open-Access Articles: Did you know that after publication, the public cannot read our research unless they pay a fee to the journal. However, for a relatively large global fee, we can change their status to “Public Access.” Learn more here >
- Doctor reported outcomes: Real-world data from a tertiary eye cancer center Abhilasha Maheshwari, Paul T Finger, Abhishek Malpani, Puneet Jain , Ankit Singh Tomar, Gaurav Garg
- Doppelgänger dilemma: Leiomyoma versus uveal melanoma Ankit Singh Tomar, Anthony Fam, Paul T. Finger, and Codrin E. Iacob
- Management and Outcomes of Unilateral Group D Tumors in Retinoblastoma Amin S, AlJboor M, Toro MD, Rejdak R, Nowomiejska K, Nazzal R, Mohammad M, Al-Hussaini M, Khzouz J, Banat S, AlJabari R, Jaradat I, Mehyar M, Sultan I, AlNawaiseh I, Yousef YA
- Patients presenting with metastases: stage IV uveal melanoma, an international study Gaurav Garg, Paul T Finger, Tero T Kivelä, E Rand Simpson, Brenda L Gallie, Svetlana Saakyan, Anush G Amiryan, Vladimir Valskiy, Kimberly J Chin, Ekaterina Semenova, Stefan Seregard, Maria Filì, Matthew Wilson, Barrett Haik, Josep Maria Caminal, Jaume Catala-Mora, Cristina Gutiérrez, David E Pelayes, Anibal Martin Folgar, Martine Johanna Jager, Mehmet Doğrusöz, Gregorius P M Luyten, Arun D Singh, Shigenobu Suzuki
